Comparative evaluation of topical cyclosporine (0.05%) and topical olopatadine (0.1%) therapy in vernal kerato conjunctivitis in paediatric age group.

Dr. Souradeep Ray; Dr. Mita Saha (Dutta Chowdhury); Dr. Md Nazarul Islam

Volume : VIII, Issue : IV, April - 2019

Comparative evaluation of topical cyclosporine (0.05%) and topical olopatadine (0.1%) therapy in vernal kerato conjunctivitis in paediatric age group.

Dr. Souradeep Ray, Dr. Mita Saha Dutta Chowdhury , Dr. Md Nazarul Islam

Abstract :

Introduction :– VKC is a chronic bilateral ocular disease which is a hypersensitivity reaction of type I & type IV. Antihistaminics, mast cell stabilisers, immunomodulators, are commonly used for treatment. Olopatadine (0.1%) (mast cell stabiliser and selective H1 receptor antagonist) has rapid onset and longer action of duration and is cost effective. Cyclosporine (.05%) is a specific T–cell inhibitor, reduces T–cell activation and expression of T–cell cytokines (IL–2 and IFN). It has a low recurrence rate and is effective for long term control of VKC. So, cyclosporins are effective in recurrent cases and more effective than topical olopatadine in management of VKC patients. Aims & Objectives :– The aim of the study is to compare the efficacy of cyclosporine (0.05%) and olopatadine (0.1%) in VKC in children in a tertiary health care centre of West Bengal during the period May 2014 to June 2016. Materials & Methods :– 134 patients with Bilateral VKC were divided into 2 groups and adviced for instillation of drops twice daily for 4 weeks and patients were assessed on 7th, 14th, & 28th day and score was given to each patient for their grades of symptom / sign and by adding up the total, score of each patient was found out. Results :– The data were analysed by Chi–square test. Using paired T–test for compå the efficacy of group A & group B drugs imply that the study is statistically significant and there is a significant difference in efficacy of both the drugs. Conclusion :– Topical cyclosporine is more effective than topical olopatadine in management of VKC patients though olopatadine is cost effective